BioNexus Gene Lab Corp. (BGLC) Gross margin 2018–2025
BioNexus Gene Lab Corp. (BGLC) gross margin by fiscal year — reported gross profit divided by reported revenue.
14.6%FY2025 · since FY2018: 13.5% → 14.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 14.6% | +1.1 pp |
| FY2024 | 13.6% | -0.0 pp |
| FY2023 | 13.6% | +2.1 pp |
| FY2022 | 11.5% | -5.4 pp |
| FY2021 | 17.0% | +1.9 pp |
| FY2020 | 15.1% | -28.9 pp |
| FY2019 | 44.0% | +30.5 pp |
| FY2018 | 13.5% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More BGLC financial trends
BGLC RevenueBGLC Net incomeBGLC Net marginBGLC Gross profitBGLC Operating incomeBGLC Operating marginBGLC Operating cash flowBGLC Free cash flowBGLC Capital expendituresBGLC Return on equityBGLC Stock buybacksBGLC Dividends paidBGLC Total assetsBGLC Total liabilitiesBGLC Shareholders’ equityBGLC overview →